DOCSLIB.ORG

Heteromeric Nicotinic Inhibition by Isoflurane Does Not Mediate MAC

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Heteromeric Nicotinic Inhibition by Isoflurane Does Not Mediate MAC Anesthesiology 2002; 97:902–5 © 2002 American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins, Inc. Heteromeric Nicotinic Inhibition by Isoflurane Does Not Mediate MAC or Loss of Righting Reflex Pamela Flood, M.D.,* James M. Sonner, M.D.,† Diane Gong, B.S.,‡ Kristen M. Coates, B.S.§ Background: Neuronal nicotinic acetylcholine receptors concentration (MAC) in rats.6 The same ratio of potency (nAChRs) have been implicated in the mechanism of action of has been observed in molluscan nAChRs.7 Thus, the isoflurane as they are inhibited at subanesthetic concentra- neuronal nAChRs fit substantial criteria for playing a role tions. Despite clear evidence for nicotinic inhibition at relevant isoflurane concentrations, it is unclear what behavioral result in the mechanism of action of isoflurane. Despite clear ensues, if any. evidence that isoflurane modulates nAChRs in a clinically Methods: The authors have modeled two behaviors common relevant concentration range, a specific behavioral tie Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/97/4/902/405875/0000542-200210000-00023.pdf by guest on 26 September 2021 to all general anesthetics, immobility and hypnosis, as mini- between isoflurane modulation of nAChRs (or any other mum alveolar concentration that prevents movement in re- putative target) has not been demonstrated. sponse to a supramaximal stimulus (MAC) and loss of righting reflex (LORR). They have tested the ability of nicotinic pharma- Anesthesia is a complex group of behaviors that is cologic modulators and congenital absence of most hetero- readily identified but not simply defined. All general meric nAChRs to affect concentration of isoflurane required for anesthetic agents have in common the propensity to these behaviors. induce immobility and hypnosis. The most commonly Results: Neither mecamylamine, 5 mg/kg, nor chlorisondam- studied anesthetic behavior is immobility in response to ine, 10 mg/kg, affected isoflurane MAC. Nicotine caused a small decrease in MAC. None of the above agents had any effect on the a noxious stimulus or MAC. Hypnosis is induced by 8,9 concentration of isoflurane required for LORR. Mice genetically isoflurane at lower concentrations than immobility. engineered to lack the ␤2 nicotinic gene product were not To provide evidence for the involvement of nicotinic different in MAC or LORR from controls. receptors in immobility and hypnosis induced by isoflu- Conclusions: Nicotinic antagonists do not cause MAC or LORR. rane, we have treated animals with specific nicotinic Inhibition of nicotinic acetylcholine receptors by isoflurane is not likely related to its ability to provide immobility and hyp- agonists and antagonists and tested animals with congen- nosis in a surgical setting. This is perhaps not surprising as the ital absence of the nicotinic ␤2 subunit. As isoflurane is inhibition of nAChRs in vitro is complete at an isoflurane con- an antagonist at heteromeric nAChRs,1,2 we hypothe- centration equal to one half of MAC. Nicotinic inhibition may, sized that treatment with other nicotinic antagonists however, be involved in anesthetic behaviors such as amnesia would potentiate the behavioral effects of isoflurane, and analgesia, which occur at lower anesthetic concentrations. whereas treatment with the agonist nicotine would re- verse them. Further, if isoflurane caused a behavioral NEURONAL nicotinic acetylcholine receptors (nAChRs) response by inhibiting a nAChR that contains the ␤2 have been implicated as potential targets of isoflurane subunit (as most do), the behavior should be absent or because the heteromeric forms of this receptor are in- reduced in the nicotinic ␤2 knockout mice. hibited at clinically relevant concentrations.1,2 The nAChRs are the most potently modulated volatile anes- thetic targets identified to date.3 Additional evidence for Methods the possible involvement of nAChRs in immobility is twofold. First, volatile compounds related to isoflurane With the approval of the University of California-San have been identified that would be predicted to have Francisco animal care committee, 36 male and 20 female anesthetic activity based on their hydrophobicity but do 129J mice were studied. In addition, we studied 15 male 4 not cause immobility in animals. These compounds are mice genetically engineered to lack the nicotinic ␤2 5 also ineffective at nAChRs. Second, isoflurane contains gene product on the background of the c57 Bl/6J strain a chiral carbon, and the stereoisomers can be separated. (␤2 knockout) and 15 closely related wild-type cous- The positive isomer is approximately 50% more potent ins.10 These mice were a gift from Professor Jean Pierre than the negative isomer at inhibiting minimum alveolar Changeux, M.D., at the Institute Pasteur, Department of Neuroscience, Paris, France. The ␤2 knockout mice have nearly absent high affinity nicotine binding in the brain. * Assistant Professor, § Senior Technician, Department of Anesthesiology, Co- lumbia University, New York. † Associate Clinical Professor, ‡ Research Asso- Residual binding in the habenula is thought to be sec- ciate, Department of Anesthesiology, University of California, San Francisco, ondary to minor expression of ␣3 and ␤4 containing California. nAChRs.10,11 Animals were housed five to a cage in the Received from the Department of Anesthesiology, Columbia University, New York, New York. Submitted for publication June 5, 2001. Accepted for publica- animal care facility for at least 1 week before experimen- tion May 21, 2002. Supported in part by grant Nos. K08GM00695 (to P.F.), and tation. The mice were exposed to 12-h cycles of light 1P01GM47818 (to J.M.S.) from the National Institute of General Medical Sci- ences, Bethesda, Maryland. and dark and had food and water ad libitum. Mice were Address reprint requests to Dr. Flood: Assistant Professor, Department of aged 6–8 weeks at the time of experimentation. Anesthesiology, Columbia University, 630 West 168th Street, New York, New York 10032. Address electronic mail to: [email protected]. Individual article Control experiments were conducted to demonstrate reprints may be purchased through the Journal Web site, www.anesthesiology.org. that central nicotinic blockade persisted over the 3 h Anesthesiology, V 97, No 4, Oct 2002 902 NICOTINIC INHIBITION DOES NOT MEDIATE MAC OR LORR 903 during which the MAC experiments were conducted. centration change. MAC was determined for each group Mice were injected with intraperitoneal mecamylamine, as the average MAC for each animal. Male and female 5 mg/kg. Mecamylamine acts at nanomolar concentra- animals were tested separately. tions to inhibit heteromeric nAChRs.12 After 3 h, mice that had been injected with mecamylamine and control Loss of Righting Reflex Testing mice were injected with nicotine, 1 mg/kg, subcutane- Mice were treated with 1 mg/kg nicotine, 5 mg/kg ously. Mice were observed for prostration. There was no mecamylamine, or 10 mg/kg chlorisondamine in saline evidence of nicotine-induced prostration in mice that by intraperitoneal injection, or with injection of the had received mecamylamine, whereas mice that re- same volume of saline as described above. Male and ceived saline were easily identified. This control exper- female animals were tested separately. A procedure was iment demonstrates that the nicotinic inhibitory effects 19 followed similar to that described by Joo et al. Mice Downloaded from http://pubs.asahq.org/anesthesiology/article-pdf/97/4/902/405875/0000542-200210000-00023.pdf by guest on 26 September 2021 of mecamylamine last at least 3 h, the longest period for were placed in a clear plastic cylinder connected to a any experiment. circle system containing CO2 absorber, fan, and oxygen source. The temperature of each mouse was determined MAC Testing rectally and maintained between 36° and 38°C using Mice were randomized to receive either 1 mg/kg nic- heating blankets. An investigator blinded to treatment otine, 5 mg/kg mecamylamine, or 10 mg/kg chlorison- and genotype determined the concentration of isoflu- damine in saline by intraperitoneal injection, or injection rane that resulted in LORR. The LORR was measured as of the same volume of saline. Nicotine, the prototypical the mean partial pressures of isoflurane bracketing pos- nicotinic agonist, was used at a dose that is effective in tural response and lack of response to placing the animal 13 nicotinic pain paradigms. Because of the short half-life in a supine position. of nicotine, animals were injected with nicotine or saline 5 min before testing at each isoflurane concentration. At Statistical Analysis least 40 min passed between each nicotine injection, the The values for MAC and LORR were calculated as the time required for nicotine to be undetectable in plas- 13,14 average of the highest isoflurane concentration tested ma. The control mice from these experiments did that resulted in movement and the lowest concentration not have significantly different MAC or loss of righting tested that did not result in movement. The results are reflex (LORR) values from animals that received a single expressed as mean Ϯ SE and are compared with an saline injection, and thus the control animals are pooled. unpaired Student t test for significant difference. P value Mecamylamine, a noncompetitive nicotinic antagonist, less than 0.05 is considered significant. was administered at 5 mg/kg, a concentration that results in plasma concentrations of approximately 0.2 ␮M when mea- sured by gas chromatography-mass spectroscopy in previ- Results ous experiments. These concentrations result in approxi- mately 50% inhibition of heteromeric nicotinic activation.12 Minimum Alveolar Concentration Chlorisondamine is an irreversible antagonist of nAChRs.15 The MAC for isoflurane was 1.47 Ϯ 0.03 for male mice Chlorisondamine, 10 mg/kg, completely blocks the loco- (table 1A) and 1.52 Ϯ 0.07 for female mice. There was motor response to nicotine.15,16 no significant difference in MAC between male and fe- Minimum alveolar concentration for isoflurane was male mice. Mice were treated with intraperitoneal determined for each mouse by a trained observer mecamylamine, 5 mg/kg, or chlorisondamine, 10 mg/kg, blinded to the drug injected or genotype.
Load more

Recommended publications
  • Synthesis and Characterization of in Vitro and in Vivo Profiles of Hydroxybupropion Analogues: Aids to Smoking Cessation
    Barrow Neurological Institute at St. Joseph's Hospital and Medical Center Barrow - St. Joseph's Scholarly Commons Neurobiology 6-24-2010 Synthesis And Characterization Of In Vitro And In Vivo Profiles Of Hydroxybupropion Analogues: Aids To Smoking Cessation Ronald J. Lukas Barrow Neurological Institute, [email protected] Ana Z. Muresan M. Imad Damaj Bruce E. Blough Xiaodong Huang See next page for additional authors Follow this and additional works at: https://scholar.barrowneuro.org/neurobiology Recommended Citation Lukas, Ronald J.; Muresan, Ana Z.; Damaj, M. Imad; Blough, Bruce E.; Huang, Xiaodong; Navarro, Hernan A.; Mascarella, S. Wayne; Eaton, J. Brek; Marxer-Miller, Syndia K.; and Carroll, F. Ivy, "Synthesis And Characterization Of In Vitro And In Vivo Profiles Of Hydroxybupropion Analogues: Aids To Smoking Cessation" (2010). Neurobiology. 280. https://scholar.barrowneuro.org/neurobiology/280 This Article is brought to you for free and open access by Barrow - St. Joseph's Scholarly Commons. It has been accepted for inclusion in Neurobiology by an authorized administrator of Barrow - St. Joseph's Scholarly Commons. For more information, please contact [email protected], [email protected]. Authors Ronald J. Lukas, Ana Z. Muresan, M. Imad Damaj, Bruce E. Blough, Xiaodong Huang, Hernan A. Navarro, S. Wayne Mascarella, J. Brek Eaton, Syndia K. Marxer-Miller, and F. Ivy Carroll This article is available at Barrow - St. Joseph's Scholarly Commons: https://scholar.barrowneuro.org/neurobiology/ 280 J. Med. Chem. 2010, 53, 4731–4748 4731 DOI: 10.1021/jm1003232 Synthesis and Characterization of in Vitro and in Vivo Profiles of Hydroxybupropion Analogues: Aids to Smoking Cessation Ronald J.
    [Show full text]
  • In Silico Methods for Drug Repositioning and Drug-Drug Interaction Prediction
    In silico Methods for Drug Repositioning and Drug-Drug Interaction Prediction Pathima Nusrath Hameed ORCID: 0000-0002-8118-9823 Submitted in total fulfilment of the requirements for the degree of Doctor of Philosophy Department of Mechanical Engineering THE UNIVERSITY OF MELBOURNE May 2018 Copyright © 2018 Pathima Nusrath Hameed All rights reserved. No part of the publication may be reproduced in any form by print, photoprint, microfilm or any other means without written permission from the author. Abstract Drug repositioning and drug-drug interaction (DDI) prediction are two fundamental ap- plications having a large impact on drug development and clinical care. Drug reposi- tioning aims to identify new uses for existing drugs. Moreover, understanding harmful DDIs is essential to enhance the effects of clinical care. Exploring both therapeutic uses and adverse effects of drugs or a pair of drugs have significant benefits in pharmacology. The use of computational methods to support drug repositioning and DDI prediction en- able improvements in the speed of drug development compared to in vivo and in vitro methods. This thesis investigates the consequences of employing a representative training sam- ple in achieving better performance for DDI classification. The Positive-Unlabeled Learn- ing method introduced in this thesis aims to employ representative positives as well as reliable negatives to train the binary classifier for inferring potential DDIs. Moreover, it explores the importance of a finer-grained similarity metric to represent the pairwise drug similarities. Drug repositioning can be approached by new indication detection. In this study, Anatomical Therapeutic Chemical (ATC) classification is used as the primary source to determine the indications/therapeutic uses of drugs for drug repositioning.
    [Show full text]
  • Cognitive, Behavioral, and Physiologic Responses John T
    Combined Nicotinic and Muscarinic Blockade in Elderly Normal Volunteers: Cognitive, Behavioral, and Physiologic Responses John T. Little, M.D., Douglas N. Johnson, Ph.D., Marcia Minichiello, M.A., Herb Weingartner, Ph.D., and Trey Sunderland, M.D. Establishing a pharmacologic model of the memory deficits scopolamine alone. Increased impairment was also seen for of Alzheimer’s disease could be an important tool in the mecamylamine 1 scopolamine condition as compared to understanding how memory fails. We examined the scopolamine alone in selected behavioral ratings. Pupil size combined effects of the muscarinic antagonist scopolamine increased when mecamylamine was added to scopolamine, and the nicotinic antagonist mecamylamine in eight normal while systolic blood pressure and pulse changed in elderly volunteers (age 61.9 6 8.3 yrs, SD). Each received concordance with ganglionic blockade. These data together four separate drug challenges (scopolamine (0.4 mg IV), with previous brain-imaging results suggest that this mecamylamine (0.2 mg/kg up to 15 mg PO), muscarinic–nicotinic drug combination may better model mecamylamine 1 scopolamine, and placebo). There was a Alzheimer’s disease than either drug alone. trend toward increased impairment in explicit memory for [Neuropsychopharmacology 19:60–69, 1998] the mecamylamine 1 scopolamine condition as compared to Published by Elsevier Science Inc. KEY WORDS: Scopolamine; Mecamylamine; Cognitive; al. 1985; Shimohama et al. 1986; Whitehouse and Au Geriatrics; Muscarinic antagonist; Nicotinic antagonist 1986; D’Amato et al. 1987; Zubenko et al. 1988), many cognitive dysfunction modeling studies have focused Given the limited animal models of Alzheimer’s disease on this system (Beatty et al.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • Lubeluzole/Mecamylamine Hydrochloride 1331 Precautions Ing Treated
    Lubeluzole/Mecamylamine Hydrochloride 1331 Precautions ing treated. Mannitol infusion has also been used to de Manzanas; Pol.: Purisole SM; Port.: Purisole; Xarope de Macas Reinetas; Rus.: Rheogluman (Реоглюман); Spain: Salcemetic†; Salmagne; Switz.: Mannitol is contra-indicated in patients with pulmo- prevent acute renal failure during cardiovascular and Cital†. nary congestion or pulmonary oedema, intracranial other types of surgery, or after trauma. bleeding (except during craniotomy), heart failure (in To reduce raised intracranial or intra-ocular pres- patients with diminished cardiac reserve, expansion of sure mannitol may be given by intravenous infusion as Mebutamate (BAN, USAN, rINN) the extracellular fluid may lead to fulminating heart a 15 to 25% solution in a dose of 0.25 to 2 g/kg over 30 Mébutamate; Mebutamato; Mebutamatum; W-583. 2-sec-Butyl- failure), and in patients with renal failure unless a test to 60 minutes. Rebound increases in intracranial or 2-methyltrimethylene dicarbamate. dose has produced a diuretic response (if urine flow is intra-ocular pressure may occur but are less frequent Мебутамат inadequate, expansion of the extracellular fluid may than with urea. C10H20N2O4 = 232.3. lead to acute water intoxication). During transurethral prostatic resection a 2.5 to 5% CAS — 64-55-1. Mannitol should not be given with whole blood. ATC — N05BC04. solution of mannitol has been used for irrigating the ATC Vet — QN05BC04. All patients given mannitol should be carefully ob- bladder. served for signs of fluid and electrolyte imbalance and Ciguatera poisoning. Ciguatera poisoning occurs throughout O O renal function should be monitored. the Caribbean and Indopacific as a result of the consumption of certain fish contaminated with ciguatoxin; it is increasingly seen Pharmacokinetics in Europe, in travellers returning from these areas, or as a result H2NO O NH2 Only small amounts of mannitol are absorbed from the of eating imported fish.
    [Show full text]
  • III IIHIIII US005574052A United States Patent (19) 11 Patent Number: 5,574,052 Rose Et Al
    III IIHIIII US005574052A United States Patent (19) 11 Patent Number: 5,574,052 Rose et al. 45) Date of Patent: *Nov. 12, 1996 54) AGONIST-ANTAGONIST COMBINATION TO Nicotine Self-Administration..., H. M. Hanson, et al., Ch. REDUCE THE USE OF NICOTINE AND 7 Norman A. Krasnegor, NIDA Research Monograph 23, OTHER DRUGS Jan. 1979. Influencing Cigarette Smoking ..., I. P. Stolerman, et. al., (75 Inventors: Jed E. Rose, Venice; Edward D. Psychopharmacologia (Berl.) 28–247-249 (1973). Levin, Los Angeles, both of Calif. Effects of Mecamylamine On Human Cigarette Smoking . , Nemeth-Coslett, et al., Pharmacology (1986) (73) Assignee: Robert J. Schaap, Los Angeles, Calif.; 88:420-425. a part interest Rapid Phsiologic Effects of Nicotine ..., J. Henningfield, et al., U.S. Dept. of Health and Human Services, 259-265. * Notice: The term of this patent shall not extend Could Nicotine Antagonists Be Used..., by I. P. Stolerman, beyond the expiration date of Pat. No. Br, Jr. of Addiction (1986) 81, 47-53. 5,316,759. Mecamylamine Pretreatment . , C. S. Pomerleau, et. al., Pharmacology (1987) 91:391-393. (21) Appl. No.: 235,454 Clinical Evaluation of Mecamylamine..., F. S. Tennant, Jr., et al., NIDA Research Monograph, Feb. 9 (1984). 239–246. (22 Filed: Apr. 29, 1994 Withdrawl From Nicotine Dependence ..., F. S. Tennant, Jr., et al., NIDA Research Monograph, 55 (1985). Related U.S. Application Data Double-Blind Comparison . , F. S. Tennant, Jr., UCLA, Los Angeles, California. 63) Continuation of Ser. No. 54,144, Apr. 30, 1993, which is a Involvement of Cholinergic Nicotine-like Receptors . continuation of Ser. No. 855,868, Mar.
    [Show full text]
  • MECAMYLAMINE Hydrochloride Tablets, USP, 2.5 Mg
    MECAMYLAMINE HYDROCHLORIDE- mecamylamine hydrochloride tablet Nexgen Pharma, Inc. ---------- MECAMYLAMINE Hydrochloride Tablets, USP, 2.5 mg DESCRIPTION Mecamylamine HCl is a potent, oral antihypertension agent and ganglion blocker, and is a secondary amine. It is N,2,3,3-tetramethyl-bicyclo [2.2.1] heptan- 2 -amine hydrochloride. Its empirical formula is C11H21N • HCl and its structural formula is: It is a white, odorless, or practically odorless, crystalline powder, is highly stable, soluble in water and has a molecular weight of 203.75. Mecamylamine HCl is supplied as tablets for oral use, each containing 2.5 mg mecamylamine HCl. Inactive ingredients are calcium phosphate, D&C Yellow 10, FD&C Yellow 6, lactose, magnesium stearate, cornstarch, and talc. CLINICAL PHARMACOLOGY Mecamylamine HCl reduces blood pressure in both normotensive and hypertensive individuals. It has a gradual onset of action (1/2 to 2 hours) and a long-lasting effect (usually 6 to 12 hours or more). A small oral dosage often produces a smooth and predictable reduction of blood pressure. Although this antihypertensive effect is predominantly orthostatic, the supine blood pressure is also significantly reduced. Pharmacokinetics and Metabolism Mecamylamine HCl is almost completely absorbed from the gastrointestinal tract, resulting in consistent lowering of blood pressure in most patients with hypertensive cardiovascular disease. Mecamylamine HCl is excreted slowly in the urine in the unchanged form. The rate of its renal elimination is influenced markedly by urinary pH. Alkalinization of the urine reduces, and acidification promotes, renal excretion of mecamylamine. Mecamylamine HCl crosses the blood-brain and placental barriers. INDICATIONS AND USAGE For the management of moderately severe to severe essential hypertension and in uncomplicated cases of malignant hypertension.
    [Show full text]
  • Neuronal Nicotinic Receptors
    NEURONAL NICOTINIC RECEPTORS Dr Christopher G V Sharples and preparations lend themselves to physiological and pharmacological investigations, and there followed a Professor Susan Wonnacott period of intense study of the properties of nAChR- mediating transmission at these sites. nAChRs at the Department of Biology and Biochemistry, muscle endplate and in sympathetic ganglia could be University of Bath, Bath BA2 7AY, UK distinguished by their respective preferences for C10 and C6 polymethylene bistrimethylammonium Susan Wonnacott is Professor of compounds, notably decamethonium and Neuroscience and Christopher Sharples is a hexamethonium,5 providing the first hint of diversity post-doctoral research officer within the among nAChRs. Department of Biology and Biochemistry at Biochemical approaches to elucidate the structure the University of Bath. Their research and function of the nAChR protein in the 1970’s were focuses on understanding the molecular and facilitated by the abundance of nicotinic synapses cellular events underlying the effects of akin to the muscle endplate, in electric organs of the acute and chronic nicotinic receptor electric ray,Torpedo , and eel, Electrophorus . High stimulation. This is with the goal of affinity snakea -toxins, principallyaa -bungarotoxin ( - Bgt), enabled the nAChR protein to be purified, and elucidating the structure, function and subsequently resolved into 4 different subunits regulation of neuronal nicotinic receptors. designateda ,bg , and d .6 An additional subunit, e , was subsequently identified in adult muscle. In the early 1980’s, these subunits were cloned and sequenced, The nicotinic acetylcholine receptor (nAChR) arguably and the era of the molecular analysis of the nAChR has the longest history of experimental study of any commenced.
    [Show full text]
  • Nicotinic Mechanisms Modulate Ethanol Withdrawal and Modify Time Course and Symptoms Severity of Simultaneous Withdrawal from Alcohol and Nicotine
    Neuropsychopharmacology (2015) 40, 2327–2336 © 2015 American College of Neuropsychopharmacology. All rights reserved 0893-133X/15 www.neuropsychopharmacology.org Nicotinic Mechanisms Modulate Ethanol Withdrawal and Modify Time Course and Symptoms Severity of Simultaneous Withdrawal from Alcohol and Nicotine 1,2 3 ,1,2,4 Erika Perez , Natalia Quijano-Cardé and Mariella De Biasi* 1 2 Department of Neuroscience, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Department of 3 4 Neuroscience, Baylor College of Medicine, Houston, TX, USA; University of Puerto Rico at Mayagüez, Mayagüez, Puerto Rico; Department of Psychiatry, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA Alcohol and nicotine are among the top causes of preventable death in the United States. Unfortunately, people who are dependent on alcohol are more likely to smoke than individuals in the general population. Similarly, smokers are more likely to abuse alcohol. Alcohol and nicotine codependence affects health in many ways and leads to poorer treatment outcomes in subjects who want to quit. This study examined the interaction of alcohol and nicotine during withdrawal and compared abstinence symptoms during withdrawal from one of the two drugs only vs both. Our results indicate that simultaneous withdrawal from alcohol and nicotine produces physical symptoms that are more severe and last longer than those experienced during withdrawal from one of the two drugs alone. In animals experiencing withdrawal after chronic ethanol treatment, acute nicotine exposure was sufficient to prevent abstinence symptoms. Similarly, symptoms were prevented when alcohol was injected acutely in mice undergoing nicotine withdrawal. These experiments provide evidence for the involvement of the nicotinic cholinergic system in alcohol withdrawal.
    [Show full text]
  • Standards, Limits and Conditions for Prescribing Dispensing And
    College of Naturopathic Physicians of British Columbia CNPBC Scope of Practice for Naturopathic Physicians: Standards, Limits and Conditions for Prescribing, Dispensing and Compounding Drugs May 27, 2010 (Edited 2021-04-30) Standards, Limits and Conditions Draft Framework ACKNOWLEDGEMENTS: The College of Naturopathic Physicians of British Columbia gratefully acknowledges the College of Registered Nurses of British Columbia (CRNBC) for permission to use material from “Scope of Practice for Nurse Practitioners (Family), Standards, Limits and Conditions”, CRNBC, April 2007; for their pioneering efforts in this area of health regulation and for their generous assistance. The College also wishes to acknowledge the extensive support and collaboration received from the College of Pharmacists of BC (CPBC). Their support and assistance has been invaluable. The CNPBC looks forward to ongoing collaboration with these and other health regulatory Colleges in the implementation of prescriptive authority for naturopathic physicians. 2 CNPBC Standards of Practice CNPBC is responsible under the Health Professions Act for setting standards of practice for its registrants. Scope of Practice Standards Scope of Practice Standards set out standards, limits and conditions related to the scope of practice for naturopathic physicians. (See Appendix A.) 3 Contents Introduction .............................................................................................................. 5 Section A – Prescribing and Dispensing PART l – Standards ................................................................................................
    [Show full text]
  • Discriminative Stimulus Effects of Mecamylamine and Nicotine In
    Pharmacology, Biochemistry and Behavior 179 (2019) 27–33 Contents lists available at ScienceDirect Pharmacology, Biochemistry and Behavior journal homepage: www.elsevier.com/locate/pharmbiochembeh Discriminative stimulus effects of mecamylamine and nicotine in rhesus monkeys: Central and peripheral mechanisms T ⁎ Colin S. Cunningham, Megan J. Moerke, Lance R. McMahon Department of Pharmacodynamics, The University of Florida, Gainesville, FL, USA ABSTRACT Mecamylamine is a non-competitive nicotinic acetylcholine receptor (nAChR) antagonist that has been prescribed for hypertension and as an off-label smoking cessation aid. Here, we examined pharmacological mechanisms underlying the interoceptive effects (i.e., discriminative stimulus effects) of mecamylamine (5.6 mg/ kg s.c.) and compared the effects of nAChR antagonists in this discrimination assay to their capacity to block a nicotine discriminative stimulus (1.78 mg/kg s.c.) in rhesus monkeys. Central (pempidine) and peripherally restricted nAChR antagonists (pentolinium and chlorisondamine) dose-dependently substituted for the me- camylamine discriminative stimulus in the following rank order potency (pentolinium > pempidine > chlorisondamine > mecamylamine). In contrast, at equi- effective doses based on substitution for mecamylamine, only mecamylamine antagonized the discriminative stimulus effects of nicotine, i.e., pentolinium, chlor- isondamine, and pempidine did not. NMDA receptor antagonists produced dose-dependent substitution for mecamylamine with the following rank order potency (MK-801 > phencyclidine > ketamine). In contrast, behaviorally active doses of smoking cessation aids including nAChR agonists (nicotine, varenicline, and cytisine), the smoking cessation aid and antidepressant bupropion, and the benzodiazepine midazolam did not substitute for the discriminative stimulus effects of mecamylamine. These data suggest that peripheral nAChRs and NMDA receptors may contribute to the interoceptive stimulus effects produced by mecamylamine.
    [Show full text]
  • Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys
    1521-0103/366/2/397–409$35.00 https://doi.org/10.1124/jpet.118.248070 THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS J Pharmacol Exp Ther 366:397–409, August 2018 Copyright ª 2018 by The American Society for Pharmacology and Experimental Therapeutics Involvement of Nicotinic Receptor Subtypes in the Behavioral Effects of Nicotinic Drugs in Squirrel Monkeys Sarah L. Withey,1 Michelle R. Doyle,1,2 Jack Bergman, and Rajeev I. Desai Preclinical Pharmacology Laboratory, McLean Hospital/Harvard Medical School, Belmont, Massachusetts Received January 27, 2018; accepted May 17, 2018 ABSTRACT Evidence suggests that the a4b2, but not the a7, subtype of the except for lobeline, the nicotinic agonists produced either full nicotinic acetylcholine receptor (nAChR) plays a key role in [(1)-epibatidine, (2)-epibatidine, and nicotine] or partial (vare- Downloaded from mediating the behavioral effects of nicotine and related drugs. nicline, cytisine, anabaseine, and isoarecolone) substitution for However, the importance of other nAChR subtypes remains (1)-epibatidine. In interaction studies with antagonists differing unclear. The present studies were conducted to examine the in selectivity, (1)-epibatidine discrimination was substan- involvement of nAChR subtypes by determining the effects of tively antagonized by mecamylamine, slightly attenuated selected nicotinic agonists and antagonists in squirrel monkeys by hexamethonium (peripherally restricted) or dihydro- b a either 1) responding for food reinforcement or 2) discriminating the -erythroidine, and not altered by methyllycaconitine ( 7 jpet.aspetjournals.org nicotinic agonist (1)-epibatidine (0.001 mg/kg) from vehicle. In selective). Varenicline and cytisine enhanced (1)-epibati- food-reinforcement studies, nicotine, (1)-epibatidine, varenicline dine’s discriminative-stimulus effects.
    [Show full text]